Hikma Pharmaceuticals PLC
LSE:HIK
| US |
|
Fubotv Inc
NYSE:FUBO
|
Media
|
| US |
|
Bank of America Corp
NYSE:BAC
|
Banking
|
| US |
|
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
| US |
C
|
C3.ai Inc
NYSE:AI
|
Technology
|
| US |
|
Uber Technologies Inc
NYSE:UBER
|
Road & Rail
|
| CN |
|
NIO Inc
NYSE:NIO
|
Automobiles
|
| US |
|
Fluor Corp
NYSE:FLR
|
Construction
|
| US |
|
Jacobs Engineering Group Inc
NYSE:J
|
Professional Services
|
| US |
|
TopBuild Corp
NYSE:BLD
|
Consumer products
|
| US |
|
Abbott Laboratories
NYSE:ABT
|
Health Care
|
| US |
|
Chevron Corp
NYSE:CVX
|
Energy
|
| US |
|
Occidental Petroleum Corp
NYSE:OXY
|
Energy
|
| US |
|
Matrix Service Co
NASDAQ:MTRX
|
Construction
|
| US |
|
Automatic Data Processing Inc
NASDAQ:ADP
|
Technology
|
| US |
|
Qualcomm Inc
NASDAQ:QCOM
|
Semiconductors
|
| US |
|
Ambarella Inc
NASDAQ:AMBA
|
Semiconductors
|
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
1 722.5
2 083
|
| Price Target |
|
We'll email you a reminder when the closing price reaches GBX.
Choose the stock you wish to monitor with a price alert.
|
|
Fubotv Inc
NYSE:FUBO
|
US |
|
|
Bank of America Corp
NYSE:BAC
|
US |
|
|
Palantir Technologies Inc
NYSE:PLTR
|
US |
|
C
|
C3.ai Inc
NYSE:AI
|
US |
|
|
Uber Technologies Inc
NYSE:UBER
|
US |
|
|
NIO Inc
NYSE:NIO
|
CN |
|
|
Fluor Corp
NYSE:FLR
|
US |
|
|
Jacobs Engineering Group Inc
NYSE:J
|
US |
|
|
TopBuild Corp
NYSE:BLD
|
US |
|
|
Abbott Laboratories
NYSE:ABT
|
US |
|
|
Chevron Corp
NYSE:CVX
|
US |
|
|
Occidental Petroleum Corp
NYSE:OXY
|
US |
|
|
Matrix Service Co
NASDAQ:MTRX
|
US |
|
|
Automatic Data Processing Inc
NASDAQ:ADP
|
US |
|
|
Qualcomm Inc
NASDAQ:QCOM
|
US |
|
|
Ambarella Inc
NASDAQ:AMBA
|
US |
This alert will be permanently deleted.
Hikma Pharmaceuticals PLC
Wall Street
Price Targets
HIK Price Targets Summary
Hikma Pharmaceuticals PLC
According to Wall Street analysts, the average 1-year price target for
HIK
is 2 331.21 GBX
with a low forecast of 2 020 GBX and a high forecast of 2 887.5 GBX.
Operating Income
Forecast
Operating Income Estimate
Hikma Pharmaceuticals PLC
For the last 8 years the
compound annual growth rate for
Hikma Pharmaceuticals PLC's operating income is
6%.
The projected
CAGR
for the next 3 years is
9%.
Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What is available on other sites you are seeing are mostly from the sell-side analysts.
What is HIK's stock price target?
Price Target
2 331.21
GBX
According to Wall Street analysts, the average 1-year price target for
HIK
is 2 331.21 GBX
with a low forecast of 2 020 GBX and a high forecast of 2 887.5 GBX.
What is Hikma Pharmaceuticals PLC's Revenue forecast?
Projected CAGR
6%
For the last 8 years the
compound annual growth rate for
Hikma Pharmaceuticals PLC's revenue is
9%.
The projected
CAGR
for the next 3 years is
6%.
What is Hikma Pharmaceuticals PLC's Operating Income forecast?
Projected CAGR
9%
For the last 8 years the
compound annual growth rate for
Hikma Pharmaceuticals PLC's operating income is
6%.
The projected
CAGR
for the next 3 years is
9%.
What is Hikma Pharmaceuticals PLC's Net Income forecast?
Projected CAGR
44%
For the last 8 years the
compound annual growth rate for
Hikma Pharmaceuticals PLC's net income is
-3%.
The projected
CAGR
for the next 3 years is
44%.
You don't have any saved screeners yet
